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 Alloimmune response and graft  rejection 
are largely T cell-mediated. T-cell 
responses (clonal expansion and eff ector 
functions) are highly regulated. T cells 
require two signals to be fully activated: 
the fi rst signal is provided by the interac-
tion between an antigen – MHC (Major 
Histocompatibility Complex) and a 
T-cell receptor, and the second is an anti-
gen-independent costimulatory signal. 
In the absence of the second signal, 
T cells fail to respond and become aner-
gic. Th ere are additional negative regula-
tors of the T-cell costimulatory pathway 
that provide signals to regulate tolerance. 
Th e balance of these positive and nega-
tive costimulatory signals determines the 
outcome of alloimmune response. Cyto-
toxic T lymphocyte-associated antigen 4 
(CTLA-4) is one of the well-known neg-
ative regulators. More recently, we have 
come to understand the existence of 
other important negative regulators of 
T-cell costimulation, including the induc-
ible T-cell costimulator (ICOS) and pro-
grammed death-1 (PD-1) pathways. 
 Negative immune regulatory function 
of PD-1 was fi rst revealed by the autoim-
mune-prone  pdcd1  – / –  mice. 1 PD-1 – defi -
cient mice develop B-cell expansion, 
autoimmune glomerulonephritis, and 
anti-troponin antibody-associated cardio-
myopathy. PD-1 is expressed on B cells, 
natural killer T cells, activated monocytes, 
dendritic cells (DCs), and activated 
T cells. Its ligand PD-L1 is constitutively 
expressed on T and B cells, DCs, macro-
phages, mesenchymal stem cells, bone 
marrow-derived mast cells, and a wide 
range of non-hematopoietic cells. PD-L1 
expression is upregulated upon activation 
by type 1 and type 2 interferons. PD-L2 
expression is much more restricted and is 
inducibly expressed on DCs, macro-
phages, and mast cells. Th ere are some 
unique aspects to PD-1 signaling. PD-1 
has a greater eff ect on cytokine produc-
tion than on cell proliferation; the inhibi-
tory eff ect of the PD-1 pathway depends 
on the relative strength of T-cell receptor 
signaling; and PD-1 signaling can be 
bidirectional. 
 PD-L1 expression is associated with 
immune privilege in the cornea and tes-
ticular tissues. 2,3 Following an allograft  
placement, both PD-1 and PD-L1 are 
signifi cantly upregulated on alloreactive 
T cells and in parenchymal tissues such 
as the heart and pancreatic islets. 4,5 In 
murine transplant models, administra-
tion of PD-L1 blocking antibodies or 
PD-L1 defi ciency on non-lymphoid tis-
sues of the donor results in accelerated 
acute rejection. However, the PD-L2 
blocking antibody does not have a simi-
lar eff ect; this suggests a unique eff ect of 
the PD-L1 pathway on the control of 
alloimmunity. In a recent study using a 
fully MHC-mismatched cardiac trans-
plant model, it was shown that PD-L1 
expression by resident immune cells are 
a prerequisite for tolerance induction by 
CTLA-4-Ig therapy. 6 
 Th ere are several mechanisms by which 
the PD-1 and PD-L1 pathway controls 
immune responses. First, PD-1 and PD-
L1 provide signals that regulate both 
central and peripheral tolerance. PD-1 –
 PD-L1 interaction inhibits positive selec-
tion of T cells during their thymic 
maturation. Self- and alloreactive T cells 
that escape thymic scrutiny are further 
controlled by PD-1 through its inhibitory 
eff ect on DC cell – T cell interaction. Addi-
tionally, PD-L1 independently promotes 
tolerance by inducing apoptosis of allore-
active T cells and by inducing and sus-
taining regulatory T cells. 7 
 Starke  et al. 8 (this issue) now examine 
the role of the PD-1 – PD-L1 pathway in 
renal alloimmune response and in human 
kidney allograft  rejection ( Figure 1 ). In 
an elegant series of experiments, the 
authors fi rst demonstrated that PD-1 lig-
ands are induced on human renal tubular 
epithelial cells activated by cytokines, 
interferon-  , and interferon-  . Using co-
culture experiments, they subsequently 
demonstrated the inhibitory effect of 
renal tubular epithelial PD-L1 on alloim-
mune T-cell responses: CD4   +   T-cell pro-
liferation and interferon-  production by 
CD4   +   and CD8   +   T cells. In this instance, 
tubular epithelial cells behave as non-
professional antigen-presenting cells. Th e 
 in vivo signifi cance of the authors ’ obser-
vation is suggested by the decreased 
expression of PD-L1 in human allograft s 
undergoing more intense cellular acute 
rejection. Th e paradoxical increase of 
PD-L1 in biopsies undergoing acute vas-
cular rejection is intriguing but falls in 
line with the observation that regulatory 
T cells are increased in this setting. 
Thus, the increase in PD-1 and other 
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 After an allograft placement, the body faces an intricate task of 
mounting a balanced immune response to foreign antigens. The ideal 
response entails maintaining enough immunity to prevent infections 
and cancer yet not endangering the ability to achieve and maintain 
organ tolerance. Programmed death-1 and its ligands expressed on 
non-professional antigen-presenting cells such as the renal tubular 
epithelium function to downregulate allogenic T-cell responses and 
thus play an important role in achieving this balance. 
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regulatory pathways in vascular rejection 
might indicate development of host 
immunoregulatory responses to the 
ongoing immune-mediated tissue injury. 
Although the findings of the current 
study are preliminary, they are important 
and are likely to stimulate additional 
investigation into therapies that modu-
late the PD-1 pathway in renal transplan-
tation and renal autoimmune disorders. 
 Some cautionary points are worth 
mentioning. First, as with other immune 
regulatory pathways, there is likely to be 
redundancy and context-dependent 
variability to the negative regulatory 
eff ect of PD-1. Second, microbes and 
cancer are known to exploit the PD-1 
pathway to evade the host immune sys-
tem. Th us, prolonged induction of the 
PD-1 pathway or use of PD-L1 agonistic 
ligands may unintentionally increase 
the risk of chronic viral infections 9 and 
cancer. 10 Careful titration of the activa-
tion state of the PD-1 pathway may be 
important to achieve a state of immuno-
logic finesse — tolerance without an 
increase in the risk of infections and 
cancer. With advances in immune 
monitoring, however, the future of 
therapeutic approaches to modulate 
alloimmune responses and achieve 
tolerance is exciting. 
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 The quest for the elusive 
causative SNP 
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 El Kares  et al. present evidence that fetal genetic variation in the 3  end 
of  ALDH1A2 may influence nephrogenesis and blood retinoic acid levels. 
This may be correct, but only replication of this association, ideally 
accounting for both the fetal and the maternal genotypes, will provide a 
better understanding of the biology that underlies the association. 
 Kidney International (2010)  78, 9 – 10.  doi: 10.1038/ki.2010.96 
 In this issue of  Kidney International , 
El Kares  et al. 1 report that fetal carriers 
of a single-nucleotide polymorphism 
(SNP) in the gene  ALDH1A2 (rs7169289) 
had bigger kidneys at birth (22 % larger 
volume, adjusted for body size), as well 
as increased retinoic acid in cord blood. 
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 Figure 1  |  An allograft model depicting PD-L1 expressed on activated renal tubular epithelial 
cells and dendritic cells and its interaction with PD-1 expressed on allogenic T cells . The renal 
tubular epithelial PD-1 pathway may promote tolerance by inhibiting alloreactive T-cell response 
and by inducing and sustaining FOXP3   +   regulatory T cells. DC, dendritic cell; PD-1, programmed 
death-1; PD-L1, ligand for PD-1. 
